ArticleMaterials (Basel, Switzerland)2026
Characterizing Multifunctional Mesoporous Cerium Silicate Nanoparticles for Potential Use in Bioactive Dental Materials: A Proof-of-Concept Study.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
(1) Background: Cerium silicate (CeSi) nanoparticles (NPs) have potential as a restorative filler particle with multifunctional properties to improve longevity. To increase the biological activity, these nanoparticles can be fabricated with ultrasmall pores (mesoporous) (MPCeSi-NP) that can be loaded with a polyphosphate inhibitor, such as gallein. (2) Methods: MPCeSi-NPs were custom-synthesized with a microemulsion method, using cetyltrimethylammonium bromide (CTAB) as a template for self-assembly. Biocompatibility with oral keratinocytes/fibroblasts was tested, with the addition of examining the biomineralization potential with human bone-marrow-derived mesenchymal stromal cells (BM-MSCs). MPCeSi-NP, loaded with gallein, was tested against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.